Head and Neck Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy.
Oral Oncol. 2009 Nov;45(11):986-90. doi: 10.1016/j.oraloncology.2009.05.635. Epub 2009 Jul 1.
Salivary gland carcinomas (SGCs) are rare tumors encompassing a wide spectrum of histologic/biologic entities. Standard non-surgical treatments are ineffective in case of advanced disease. Our aim was to analyze SGCs deregulation gene profiles that could become target for innovative treatment options. Samples from 139 patients with primary, recurrent and/or metastatic SGCs were investigated by immunohistochemistry for protein encoded by tyrosine kinases receptors (TKRs) i.e. c-kit, HER2, EGFR and hormonal receptors, i.e. androgen (AR), estrogen (ER) and progesterone receptors (PgR). In 26 cases, the HER2 immunohistochemical analysis was complemented by fluorescence in-situ hybridization analysis. EGFR was the most expressed TKRs (71%) and it was found across all histotypes. c-Kit expression was mainly restricted to adenoid cystic carcinoma (78%) while HER2 expression, mostly sustained by gene amplification, correlated with salivary duct carcinoma (SDC) in 44% of cases and adenocarcinoma, not otherwise specified (AD, NOS) in 21% of cases. With respect to histogenetic classification, TKRs expression occurred more often in tumors derived from intercalated duct rather than excretory ones with the only exception of HER2. AR was found in 13% of samples, restricted to SDC and AD, NOS and it was co-expressed with HER2 in more than half of the SDC cases. ER and PgR positivity was never detected. This TK-hormonal receptors analysis identify a histotype-specific profiles that could be exploited for better selecting patients for innovative treatment within prospective studies.
唾液腺癌（SGC）是一种罕见的肿瘤，包含广泛的组织学/生物学实体。标准的非手术治疗在晚期疾病中无效。我们的目的是分析 SGC 失调基因谱，这些基因谱可能成为创新治疗选择的靶点。通过免疫组织化学法对 139 例原发性、复发性和/或转移性 SGC 患者的组织样本进行了蛋白编码酪氨酸激酶受体（TKRs），即 c-kit、HER2、EGFR 和激素受体，即雄激素（AR）、雌激素（ER）和孕激素受体（PgR）的检测。在 26 例病例中，HER2 免疫组织化学分析用荧光原位杂交分析进行了补充。EGFR 是表达最广泛的 TKRs（71%），存在于所有组织类型中。c-Kit 表达主要局限于腺样囊性癌（78%），而 HER2 表达，主要由基因扩增维持，与唾液导管癌（SDC）相关，占 44%的病例，与腺癌，非特殊型（AD，NOS）相关，占 21%的病例。根据组织发生分类，TKRs 表达在来源于间充质导管的肿瘤中比来源于排泄导管的肿瘤更常见，HER2 是唯一的例外。AR 在 13%的样本中被发现，仅限于 SDC 和 AD，NOS，并且在超过一半的 SDC 病例中与 HER2 共同表达。从未检测到 ER 和 PgR 阳性。这项 TK-激素受体分析确定了一种组织类型特异性的特征，这些特征可以在未来的研究中更好地选择接受创新治疗的患者。
